Entrada Therapeutics Files Q1 2025 10-Q

Ticker: TRDA · Form: 10-Q · Filed: May 8, 2025 · CIK: 1689375

Entrada Therapeutics, Inc. 10-Q Filing Summary
FieldDetail
CompanyEntrada Therapeutics, Inc. (TRDA)
Form Type10-Q
Filed DateMay 8, 2025
Risk Levelmedium
Sentimentneutral

Sentiment: neutral

Topics: 10-Q, SEC Filing, Pharmaceuticals, Financials

TL;DR

Entrada Therapeutics filed its Q1 2025 10-Q, check financials.

AI Summary

Entrada Therapeutics, Inc. filed its quarterly report for the period ending March 31, 2025. The company, formerly known as CycloPorters, Inc., is based in Boston, MA, and operates in the pharmaceutical preparations sector. The filing details financial information and operational updates for the first quarter of 2025.

Why It Matters

This filing provides investors and stakeholders with a crucial update on Entrada Therapeutics' financial health and operational progress during the first quarter of 2025.

Risk Assessment

Risk Level: medium — As a pharmaceutical company, Entrada Therapeutics is subject to inherent risks related to drug development, regulatory approvals, and market competition.

Key Numbers

  • 20250331 — Reporting Period End Date (Indicates the end of the fiscal quarter for which financial data is reported.)
  • 20250508 — Filing Date (The date the 10-Q report was officially submitted to the SEC.)

Key Players & Entities

  • Entrada Therapeutics, Inc. (company) — Filer of the 10-Q
  • CycloPorters, Inc. (company) — Former name of Entrada Therapeutics
  • 20250331 (date) — End of the reporting period
  • 20250508 (date) — Filing date
  • Boston, MA (location) — Company headquarters

FAQ

What is the primary business of Entrada Therapeutics, Inc.?

Entrada Therapeutics, Inc. operates in the Pharmaceutical Preparations sector, SIC code 2834.

What was the previous name of Entrada Therapeutics, Inc.?

The company was formerly known as CycloPorters, Inc., with a name change date of November 4, 2016.

For which fiscal period is this 10-Q report filed?

This 10-Q report is filed for the period ending March 31, 2025.

Where is Entrada Therapeutics, Inc. headquartered?

Entrada Therapeutics, Inc. is headquartered in Boston, MA, with its business address at One Design Center Place, Suite 17-500.

What is the SEC file number for Entrada Therapeutics, Inc.?

The SEC file number for Entrada Therapeutics, Inc. is 001-40969.

Filing Details

This Form 10-Q (Form 10-Q) was filed with the SEC on May 8, 2025 regarding Entrada Therapeutics, Inc. (TRDA).

View full filing on EDGAR

View Full Filing

View this 10-Q filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.